FindTrial
Sign In

Neoadjuvant pembrolizumab plus chemotherapy in locally advanced sinonasal carcinoma (NeoPeSino)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-505917-25-00
Acronym
NeoPeSino
Enrollment
28
Registered
2023-10-27
Start date
2024-11-05
Completion date
Unknown
Last updated
2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced sinonasal carcinoma

Brief summary

Neoadjuvant therapy objective response rate (ORR, defined as the sum of complete remission (CRs) and partial responses (PRs) by RECIST v. 1.1 criteria will serve as the primary efficacy endpoint.

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Sponsors

Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Neoadjuvant therapy objective response rate (ORR, defined as the sum of complete remission (CRs) and partial responses (PRs) by RECIST v. 1.1 criteria will serve as the primary efficacy endpoint.—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026